Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: Development of extracutaneous lymphoma in 6 patients
- 21/08/11
Doi : 10.1016/j.jaad.2005.02.055
Saskia A. Bouwhuis, MD a, Mark D.P. Davis, MD a, ⁎, Rokea A. el-Azhary, MD a, Marian T. McEvoy, MD a, Lawrence E. Gibson, MD a, John M. Knudsen, MD b, Joseph M. Kist, MD a, Mark R. Pittelkow, MD a
a From the Departments of Dermatology
b Radiology, Mayo Clinic
Correspondence to: Mark D. P. Davis, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.Rochester, Minnesota
Abstract |
Bexarotene is a retinoid drug that is approved for the treatment of cutaneous T-cell lymphoma. We report 6 cases in which the initiation of bexarotene therapy for cutaneous T-cell lymphoma was temporally associated with the progression of internal disease despite improvement in cutaneous signs and symptoms. It is possible that bexarotene contributed to this progression. Although bexarotene therapy may alleviate symptoms and signs of cutaneous T-cell lymphoma, careful surveillance of lymph nodes and solid organs during treatment is advised.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None. Nothing in this article implies endorsement of the products of Ligand Pharmaceuticals. |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 52 - N° 6
P. 991-996 - juin 2005 Retour au numéro
Article précédent
- Sterility of stored nonanimal, stabilized hyaluronic acid gel syringes after patient injection
- Supriya G. Bellew, Karen C. Carroll, Margaret A. Weiss, Robert A. Weiss
- Availability of Journal Back Issues
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?